Monitor upcoming Q3 2026 earnings for initial impact of aprevo Lumbar CMS reimbursement (effective Oct 1) and product launches on revenue trajectory. The CFO transition is routine but Heppenstall's orthopedic/medtech background may signal continued operational focus.
Price Chart
Executive Summary
Carlsmed announced the appointment of Richard Heppenstall as CFO, replacing Leo Greenstein. The company reaffirmed its full-year 2026 revenue guidance of $74M-$78M (50% YoY growth at midpoint), but Q2 2026 EPS of -$0.39 was a slight miss vs consensus of -$0.39 (within rounding). The CFO change and reaffirmed guidance are routine events with no material financial surprise.
Key Financial Metrics
Key Facts
- Richard Heppenstall appointed CFO effective immediately, succeeding Leo Greenstein
- Full-year 2026 revenue guidance reaffirmed at $74M-$78M, representing ~50% growth over 2025 at midpoint
- Q2 2026 EPS of -$0.39 vs consensus -$0.39 (in-line, slight miss within rounding)
- New aprevo Lumbar CMS reimbursement effective October 1, upcoming product launches noted
Financial Impact
No material financial impact from CFO change; guidance reaffirmed at $74M-$78M revenue for FY2026
Risk Factors
- CFO transition could cause near-term operational disruption
- Revenue guidance depends on successful CMS reimbursement adoption and new product launches
- Company remains pre-profitability with negative EPS
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3369860 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 12d ago | 144 | $13.85 | awaiting T+20 | — | $14.91 (+7.65%) |
Sep 30, 2026 26d ago | 8-K | $14.07 | awaiting T+20 | — | $14.91 (+5.97%) |
Sep 28, 2026 28d ago | Press Release | $14.18 $14.91 | ▲ +5.15% | ▲ +5.18% | $14.91 (+5.15%) |
Sep 15, 2026 5w ago | Insider Buy | $15.31 $14.47 | ▼ −5.49% | ▼ −8.66% | $14.91 (−2.61%) |
Aug 24, 2026 9w ago | EFFECT | $15.80 $15.42 | ▼ −2.41% | ▼ −3.72% | $14.91 (−5.63%) |
Jul 22, 2026 13w ago | Press Release | $11.00 $16.50 | ▲ +50.00% | ▲ +46.69% | $14.91 (+35.55%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers